These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 647625)

  • 1. Monocyte function in patients with solid neoplasms during immunotherapy with Corynebacterium parvum.
    Scheinberg MA; Masuda A; Maluf JA; Mendes NF
    Cancer; 1978 May; 41(5):1761-4. PubMed ID: 647625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of immunotherapy with Corynebacterium parvum and methanol extraction residue of BCG administered intravenously on host defense function in cancer patients.
    Hersh EM; Murphy SG; Quesada JR; Gutterman JU; Gschwind CR; Morgan J
    J Natl Cancer Inst; 1981 Jun; 66(6):993-1002. PubMed ID: 6941048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
    Biran H; Moake JL; Reed RC; Gutterman JU; Hersh EM; Freireich EJ; Mavligit GM
    Br J Cancer; 1976 Nov; 34(5):493-9. PubMed ID: 999783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoattractant properties of Corynebacterium parvum and pyran copolymer for human monocytes and neutrophils.
    Majeski JA; Stinnett JD
    J Natl Cancer Inst; 1977 Mar; 58(3):781-3. PubMed ID: 839571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects.
    Purves EC; Snell M; Cope WA; Addison IE; Copland RF; Berenbaum MC
    Br J Urol; 1979 Aug; 51(4):278-82. PubMed ID: 380732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings.
    Israël L; Edelstein R; Depierre A; Dimitrov N
    J Natl Cancer Inst; 1975 Jul; 55(1):29-33. PubMed ID: 1080521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corynebacterium parvum as an immunotherapeutic anticancer agent.
    Scott MT
    Semin Oncol; 1974 Dec; 1(4):367-78. PubMed ID: 4620441
    [No Abstract]   [Full Text] [Related]  

  • 8. Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function.
    Hedley DW; Nyholm RE; Currie GA
    Br J Cancer; 1979 May; 39(5):558-65. PubMed ID: 486312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy with Corynebacterium parvum in disseminated cancer.
    Israel L
    Ann N Y Acad Sci; 1976; 277(00):241-51. PubMed ID: 187100
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preliminary considerations on the intravenous use of Corynebacterium parvum in the treatment of solid neoplasms].
    Scheinberg MA; Sartori JP; de Pinho JG
    AMB Rev Assoc Med Bras; 1979 Apr; 25(4):139-40. PubMed ID: 315598
    [No Abstract]   [Full Text] [Related]  

  • 11. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. IX. Macrophage content of tumors in mice.
    Gebhardt MC; Fisher B
    J Natl Cancer Inst; 1979 Apr; 62(4):1035-41. PubMed ID: 285276
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonspecific immunotherapy by Corynebacterium parvum: phase I toxicity study in 12 patients with advanced cancer.
    Cheng VS; Suit HD; Wang CC; Cummings C
    Cancer; 1976 Apr; 37(4):1687-95. PubMed ID: 769937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity from cancer immunotherapy.
    Dosik GM; Gutterman JU; Hersh EM; Akhtar M; Sonoda T; Horn RG
    Ann Intern Med; 1978 Jul; 89(1):41-6. PubMed ID: 666183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological response in patients receiving Corynebacterium parvum therapy.
    Osborn DE; Castro JE
    Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
    [No Abstract]   [Full Text] [Related]  

  • 15. Corynebacterium parvum.
    Delmonte L; Oettgen HF; Hirshaut Y; Pinsky CM; Wanebo HJ
    Clin Bull; 1976; 6(1):31-4. PubMed ID: 1269143
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.
    Gill PG; Waller CA; MacClennan IC; Morris PJ
    Br J Cancer; 1980 May; 41(5):782-9. PubMed ID: 7426303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some "pharmacologic' data about Corynebacterium parvum.
    Israel L
    Recent Results Cancer Res; 1980; 75():88-91. PubMed ID: 7232843
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.
    James K; Clunie GJ; Woodruff MF; McBride WH; Stimson WH; Drew R; Catty D
    Br J Cancer; 1975 Sep; 32(3):310-22. PubMed ID: 61040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of Corynebacterium parvum presensitization to modify the antitumor effects of systemic and local therapeutic injections of C. parvum in mice.
    Scott MT
    J Natl Cancer Inst; 1976 Mar; 56(3):675-7. PubMed ID: 815560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the classical and alternate pathways of complement by Corynebacterium parvum.
    McBride WH; Weir DM; Kay AB; Pearce D; Caldwell JR
    Clin Exp Immunol; 1975 Jan; 19(1):143-7. PubMed ID: 1204238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.